|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristic** | **c-TREnd subpopulation (N=46)** | **Original TREnd population (N=115)** | **p-value** |
| Age (range) | 64 (39-82) | 65 (38-82) | 0.7 |
| ECOG performance status012 | 37 (81%)8 (17%)1 (2%)  | 88 (76%)25 (22%)2 (2%) | 0.9 |
| Sites of metastasesVisceralBone-onlyOther non-visceral | 33 (72%)5 (11%)8 (17%) | 87 (76%)9 (8%)19 (16%) | 0.8 |
| Number of prior lines of endocrine therapy received for advanced disease0 lines1 line2 lines3 lines | 030 (65%)16 (35%)0  | 1 (1%)\*79 (68%)33 (29%)2 (2%)\* | 0.8 |
| Duration of most recent endocrine therapy received No prior endocrine therapy 6 months>6 months | 08 (17%)38 (83%) | 1 (1%)\*30 (26%)84 (73%) | 0.5 |
| Endocrine therapy most recently received prior to enrolment  No prior endocrine therapyAromatase inhibitorFulvestrant | 027 (59%)19 (41%) | 1 (1%)\*63 (55%)51 (44%) | 0.8 |
| Receipt of prior chemotherapy for advanced disease?YesNo | 9 (20%)37 (80%) | 35 (30%)80 (70%) | 0.2 |
| Total number of prior lines of systemic therapy for advanced disease0 lines1 line2 lines3 lines4 lines | 025 (54%)17 (37%)4 (9%)0 | 1 (1%)\*55 (48%)47 (41%)11 (9%)1 (1%)\* | 0.9 |
| Clinical benefit observed on trial?YesNo | 28 (61%)18 (39%) | 66 (57%)49 (43%) | 0.7 |

**Supplementary Table 1**: Baseline characteristics of studied c-TREnd biomarker population – including all patients with at least one sample available for analysis at any timepoint(s), compared to the overall original TREnd cohort. Fisher exact test was used to calculate p-values.

\*Denotes patients included in intention-to-treat population of TREnd, despite breach of eligibility criteria (discovered post-enrolment).